Sarah Ferber - Orgenesis Insider

Orgenesis Inc -- USA Stock  

USD 0.37  0.03  7.5%

Chief Scientific Officer

Prof. Sarah Ferber, Ph.D., is Chief Scientific Officer of Orgenesis Inc. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a postdoctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Ferbers breakthrough discovery suggested that humans carry their own stemcells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferbers lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferbers research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
Age: 59  Executive Since 2012      
480-659-6404  http://www.orgenesis.com
Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.

Management Efficiency

The company has return on total asset (ROA) of (20.6) % which means that it has lost $20.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (114.75) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 71.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis Inc has Current Ratio of 0.31 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Found 14 records

EXECUTIVE Since

FRCPC MDDel Mar Pharmaceuticals Inc
N/A
David AndersonVBI Vaccines Inc
2015
Rishi GuptaDimension Therapeutics Inc
2015
Tien MDNantKwest Inc
N/A
Ayelet HornVascular Biogenics Ltd
2007
Jacob GeorgeVascular Biogenics Ltd
2000
Sam WadsworthDimension Therapeutics Inc
N/A
Shayla ForsterVBI Vaccines Inc
2015
Eric MDDimension Therapeutics Inc
N/A
Samuel WadsworthDimension Therapeutics Inc
2013
Mary ThistleDimension Therapeutics Inc
2017
Ross TuboVericel Corporation
2014
David ReckerVericel Corporation
2014
Eric CrombezDimension Therapeutics Inc
2014

Entity Summary

Orgenesis Inc., a biopharmaceutical company, develops transdifferentiation technologies in the field of cell therapy and regenerative medicine. Orgenesis Inc (ORGS) is traded on OTC Market in USA. It is located in MARYLAND, U.S.A and employs 63 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Orgenesis Inc to your portfolio

Top Management

Orgenesis Inc Leadership Team
David Sidransky, Director
Yaron Adler, Director
Marie Bouillez, Director
Neil Reithinger, CFO
Scott Carmer, CEO
Etti Hanochi, Director, MBA
Hugues Bultot, Director
Guy Yachin, Director, MBA
Chris Buyse, Director
Vered Caplan, Chairman
Sarah Ferber, Executive

Stock Performance

Orgenesis Performance Indicators